Irbesartan Modified Released Tablets Of Instruction
Common name:Irbesartan Modified Released Tablets
Trade name: Ibartain MR
The English name :Irbesartan modified released Tablets
This article main ingredients for Irbesartan, each containing 150 mg for Irbesartan.
This product is a slow release tablets, unlike ordinary tablets, it in gastrointestinal release slowly, so the effect lasts for 24 hours.
¡¾ characteristics ¡¿ this product is white or kind of white tablets.
¡¾ pharmacology and toxicology ¡¿ This product for Angiotensin ¢ò (Angiotensin ¢ò, Ang ¢ò) receptor inhibitor, can inhibit Ang ¢ñ into Ang ¢ò, can specific antagonist of Angiotensin converting enzyme 1 (AT1) receptor antagonism between the AT1 is greater than the AT2 8500 times, by selectively blocking Ang ¢ò with the combination of AT1 receptors, inhibit vasoconstriction and the release of aldosterone, antihypertensive effect. This product does not inhibit angiotensin converting enzyme (ACE), renin, other hormone receptor, nor restrain and regulate blood pressure and sodium balance of ion channels.
¡¾The pharmacokinetic ¡¿ According to clinical trial reports, this product should be taken after a meal, and the general comparison, relative bioavailability equivalent, single dose delivery, its Tmax is 3 to 5 hours, Cmax is about 1.4 ug/ml, more dosage of medicine, its Tmax is 3 to 5 hours, Cmax is about 1.5 ug/ml, have obvious ustained release effect. This product and metabolites after biliary tract and kidney excretion. The tablets release slowly, should after meals that can be absorbed completely.
¡¾Indications¡¿
high blood pressure
¡¾Dosege and Administration¡¿
Oral: the recommended starting dose of 0.15 g, once daily . According to the condition can be increased to 0.3 g,once daily .If two times a day, taking a week still is invalid, please turn to take other medicine.
¡¾ Side Effect ¡¿ Common adverse reactions: headache, dizziness, palpitation, cough occasionally, general degree is slight and transient, the most to continue taking drugs are tolerated. Rare urticaria and angioneurotic edema occurred. Literature on this product is: the incidence of adverse reactions to more than 1% of indigestion, stomach burning, diarrhea, skeletal muscle soreness, fatigue and upper respiratory tract infection, but than with the blank control group without significant difference. Incidence of greater than 1% but less than the control group with abdominal pain, anxiety, nervousness, chest pain, sore throat, nausea and vomiting, rash, tachycardia and so on. Low blood pressure and incidence of orthostatic hypotension is about 0.4%.
¡¾Contraindications¡¿This article allergies are disabled.
¡¾Matters needing attention ¡¿
1. Before starting treatment should be correct blood volume is insufficient and (or) the lack of sodium.
2. The renal insufficiency patients may need to reduce the dose of this product. And pay attention to the change of blood urea nitrogen, serum creatinine and potassium. As the renin - angiotensin and aldosterone inhibits the result of the individual sensitive patients renal function changes may be produced.
3. Hepatic insufficiency, elderly patients when using this product do not need to adjust the dosage.
4. Irbesartan cannot be discharged by hemodialysis.
¡¾Pregnant women and nursing mothers drug ¡¿Pregnant women and nursing mothers are prohibited.
¡¾Medicine for children¡¿No younger than 18 patients medication safety information.
¡¾Drug interactions¡¿
1. This product with diuretics share should be paid attention to when the blood volume is insufficient, or because of a low sodium can cause low blood pressure. With potassium-sparing diuretics (such as triamterene) share, should avoid to potassium.
2. This product with no significant interactions between warfarin.
3. With digitalis drugs such as digoxin, beta blockers, such as atenolol, calcium antagonists, such as Nitrate benzene, pyridine share pharmacokinetic do not affect each other.
¡¾Drug overdose¡¿After an overdose of the product may appear low blood pressure, bradycardia or tachycardia, vomiting, gastric lavage and support therapy should be adopted.
¡¾ specification ¡¿ (1) 150 mg
¡¾ storage ¡¿ sealed preservation.
¡¾ packing ¡¿ 30 piece of carton
¡¾The period of validity¡¿ Two years
¡¾Production enterprise¡¿Vellparm Company Limited VN
The retail price£º100RMB/box/30 pieces |
